Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.

Jedidiah I Morton Clara Marquina Jonathan Edward Shaw Danny Liew Kevan R Polkinghorne Zanfina Ademi Dianna J Magliano

Published in: Diabetologia (2022)

At current prices, use of SGLT2is, but not GLP-1 RAs, would be cost-effective when considering only their cardiovascular and kidney disease benefits for people with type 2 diabetes.

Keyphrases

risk factors
rheumatoid arthritis
disease activity
ankylosing spondylitis
systemic lupus erythematosus